You are here: Home » News-CM » Companies » News
Business Standard

Glenmark Pharmaceuticals receives tentative approval for Dabigatran Etexilate Capsules

Capital Market 

From USFDA

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg, the generic version of Pradaxa Capsules, 75 mg, 110 mg and 150 mg of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IMS Health sales data for the 12 month period ending February 2017, the Pradaxa Capsules, 75 mg, 110 mg and 150 mg market1 achieved annual sales of approximately $913 million.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Glenmark Pharmaceuticals receives tentative approval for Dabigatran Etexilate Capsules

From USFDA

From USFDA

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg, the generic version of Pradaxa Capsules, 75 mg, 110 mg and 150 mg of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IMS Health sales data for the 12 month period ending February 2017, the Pradaxa Capsules, 75 mg, 110 mg and 150 mg market1 achieved annual sales of approximately $913 million.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Glenmark Pharmaceuticals receives tentative approval for Dabigatran Etexilate Capsules

From USFDA

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg, the generic version of Pradaxa Capsules, 75 mg, 110 mg and 150 mg of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IMS Health sales data for the 12 month period ending February 2017, the Pradaxa Capsules, 75 mg, 110 mg and 150 mg market1 achieved annual sales of approximately $913 million.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22